The most common treatment-related adverse events (TRAEs) of grade 3-4 were anemia 5 (12.8%), neutropenia 5 (12.8%), leukopenia 4 (10.3%), hand-foot syndrome 3 (7.7%), thrombocytopenia 3 (7.7%), asthenia 2 (5.2%), increased aspartate aminotransferase 1 (2.6%), and increased alanine aminotransferase 1 (2.6%). The gene discussed is GPT; the disease is neutropenia.